Abstract
Sepsis remains a major global health issue in pediatric and adult populations, largely due to a lack of understanding of its complex pathophysiology. Despite its high mortality rate, there have been few advancements in sepsis-specific therapies over recent decades. The study aimed to investigate the potential benefits of a genome-wide transcriptomic approach to sepsis in pediatric and adult populations in reducing sepsis-related mortality and enhancing sepsis guidelines. The scoping review explored gene expression data pertinent to developing sepsis guidelines related to its definition, classification, disease severity, molecular biomarking, and benchmarking. A system-biology approach using transcriptomics was adopted to enhance the understanding of sepsis at the mRNA gene expression level. The study involved a search of the PubMed database for original research or systematic reviews that involved transcriptomic application in the context of clinical sepsis published over a ten-year period, from 2012-2022. Of the 14,048 studies retrieved, a full-text analysis was performed. Five main concepts emerged: case definition, classification, quantifying severity of sepsis, transcriptomic biomarkers, and benchmarking. Studies were categorized according to these five categories. The results showed evidence of a connection between the transcript and clinical sepsis, demonstrating that transcript-driven sepsis categorization is possible. Integrating transcriptomic data with clinical endpoints holds promise for more precise sepsis treatment. Although further exploration is needed, the methodology shows potential for disease modification.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
There were no funding requirements for this study
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
In this scoping review, information was used that was already in the Public Domain
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
The search process has been updated with a more focused research question
Data Availability
All cited literature has been used for this scoping review and is available as per the references provided according to journals in the public domain.
